132 related articles for article (PubMed ID: 30472704)
1. Urinary Level of Liver-Type Fatty Acid Binding Protein Reflects the Degree of Tubulointerstitial Damage in Polycystic Kidney Disease.
Watanabe S; Ichikawa D; Sugaya T; Ohata K; Inoue K; Hoshino S; Kimura K; Shibagaki Y; Kamijo-Ikemori A
Kidney Blood Press Res; 2018; 43(6):1716-1729. PubMed ID: 30472704
[TBL] [Abstract][Full Text] [Related]
2. The Possibility of Urinary Liver-Type Fatty Acid-Binding Protein as a Biomarker of Renal Hypoxia in Spontaneously Diabetic Torii Fatty Rats.
Tanabe J; Ogura Y; Nakabayashi M; Nagai Y; Watanabe S; Sugaya T; Ohata K; Ichikawa D; Inoue K; Hoshino S; Kimura K; Shibagaki Y; Ono Y; Kamijo-Ikemori A
Kidney Blood Press Res; 2019; 44(6):1476-1492. PubMed ID: 31734667
[TBL] [Abstract][Full Text] [Related]
3. Relationship between Urinary Liver-Type Fatty Acid-Binding Protein (L-FABP) and Sarcopenia in Spontaneously Diabetic Torii Fatty Rats.
Tanabe J; Ogura Y; Kosaki K; Nagai Y; Sugaya T; Ohata K; Watanabe S; Ichikawa D; Inoue K; Hoshino S; Kimura K; Maeda S; Shibagaki Y; Kamijo-Ikemori A
J Diabetes Res; 2020; 2020():7614035. PubMed ID: 32405506
[TBL] [Abstract][Full Text] [Related]
4. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease.
Lager DJ; Qian Q; Bengal RJ; Ishibashi M; Torres VE
Kidney Int; 2001 Jan; 59(1):126-36. PubMed ID: 11135065
[TBL] [Abstract][Full Text] [Related]
5. Age-Related Alterations in Blood Biochemical Characterization of Hepatorenal Function in the PCK Rat: A Model of Polycystic Kidney Disease.
Shimomura Y; Brock WJ; Ito Y; Morishita K
Int J Toxicol; 2015; 34(6):479-90. PubMed ID: 26503599
[TBL] [Abstract][Full Text] [Related]
6. Chronic Exercise Protects against the Progression of Renal Cyst Growth and Dysfunction in Rats with Polycystic Kidney Disease.
Qiu J; Sato Y; Xu L; Miura T; Kohzuki M; Ito O
Med Sci Sports Exerc; 2021 Dec; 53(12):2485-2494. PubMed ID: 34310502
[TBL] [Abstract][Full Text] [Related]
7. Utility of urinary tubular markers for monitoring chronic tubulointerstitial injury after ischemia-reperfusion.
Ichikawa D; Kamijo-Ikemori A; Sugaya T; Ohata K; Hisamichi M; Hoshino S; Kimura K; Shibagaki Y
Nephrology (Carlton); 2018 Apr; 23(4):308-316. PubMed ID: 28063188
[TBL] [Abstract][Full Text] [Related]
8. Urinary exosomal expression of activator of G protein signaling 3 in polycystic kidney disease.
Keri KC; Regner KR; Dall AT; Park F
BMC Res Notes; 2018 Jun; 11(1):359. PubMed ID: 29880041
[TBL] [Abstract][Full Text] [Related]
9. Dietary n-3 polyunsaturated fatty acids or soy protein isolate did not attenuate disease progression in a female rat model of autosomal recessive polycystic kidney disease.
Maditz KH; Oldaker C; Nanda N; Benedito V; Livengood R; Tou JC
Nutr Res; 2014 Jun; 34(6):526-34. PubMed ID: 25026920
[TBL] [Abstract][Full Text] [Related]
10. [L-type fatty acid binding protein (L-FABP) and kidney disease].
Kamijo-Ikemori A; Sugaya T; Kimura K
Rinsho Byori; 2014 Feb; 62(2):163-70. PubMed ID: 24800492
[TBL] [Abstract][Full Text] [Related]
11. Urinary liver type fatty acid binding protein in diabetic nephropathy.
Kamijo-Ikemori A; Sugaya T; Ichikawa D; Hoshino S; Matsui K; Yokoyama T; Yasuda T; Hirata K; Kimura K
Clin Chim Acta; 2013 Sep; 424():104-8. PubMed ID: 23727660
[TBL] [Abstract][Full Text] [Related]
12. Increased water intake decreases progression of polycystic kidney disease in the PCK rat.
Nagao S; Nishii K; Katsuyama M; Kurahashi H; Marunouchi T; Takahashi H; Wallace DP
J Am Soc Nephrol; 2006 Aug; 17(8):2220-7. PubMed ID: 16807403
[TBL] [Abstract][Full Text] [Related]
13. [Urinary L-type fatty acid binding protein (L-FABP) as a new urinary biomarker promulgated by the Ministry of Health, Labour and Welfare in Japan].
Kamijo-Ikemori A; Ichikawa D; Matsui K; Yokoyama T; Sugaya T; Kimura K
Rinsho Byori; 2013 Jul; 61(7):635-40. PubMed ID: 24205707
[TBL] [Abstract][Full Text] [Related]
14. Renoprotective effects of voluntary running exercise training on aldosterone-induced renal injury in human L-FABP chromosomal transgenic mice.
Kosaki K; Sugaya T; Ohata K; Tanabe J; Hoshino S; Inoue K; Kimura K; Maeda S; Shibagaki Y; Kamijo-Ikemori A
Hypertens Res; 2019 Oct; 42(10):1518-1527. PubMed ID: 31168059
[TBL] [Abstract][Full Text] [Related]
15. Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease.
Zoja C; Corna D; Locatelli M; Rottoli D; Pezzotta A; Morigi M; Zanchi C; Buelli S; Guglielmotti A; Perico N; Remuzzi A; Remuzzi G
Nephron; 2015; 129(1):52-61. PubMed ID: 25531096
[TBL] [Abstract][Full Text] [Related]
16. Epithelial-to-mesenchymal transition in cyst lining epithelial cells in an orthologous PCK rat model of autosomal-recessive polycystic kidney disease.
Togawa H; Nakanishi K; Mukaiyama H; Hama T; Shima Y; Sako M; Miyajima M; Nozu K; Nishii K; Nagao S; Takahashi H; Iijima K; Yoshikawa N
Am J Physiol Renal Physiol; 2011 Feb; 300(2):F511-20. PubMed ID: 21084407
[TBL] [Abstract][Full Text] [Related]
17. Oxidative Stress and Mitochondrial Abnormalities Contribute to Decreased Endothelial Nitric Oxide Synthase Expression and Renal Disease Progression in Early Experimental Polycystic Kidney Disease.
Kahveci AS; Barnatan TT; Kahveci A; Adrian AE; Arroyo J; Eirin A; Harris PC; Lerman A; Lerman LO; Torres VE; Irazabal MV
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183375
[TBL] [Abstract][Full Text] [Related]
18. Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage.
Yokoyama T; Kamijo-Ikemori A; Sugaya T; Hoshino S; Yasuda T; Kimura K
Am J Pathol; 2009 Jun; 174(6):2096-106. PubMed ID: 19435794
[TBL] [Abstract][Full Text] [Related]
19. [Effect of a modified low protein and low fat diet on histologic changes and metabolism in kidneys in an experimental model of polycystic kidney disease].
Banković-Calić N; Ogbori MR; Nicman E
Srp Arh Celok Lek; 2002; 130(7-8):251-7. PubMed ID: 12585002
[TBL] [Abstract][Full Text] [Related]
20. Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease.
Yang X; Zhang B; Lu X; Yan M; Wen Y; Zhao T; Li P
BMC Complement Altern Med; 2016 Jul; 16():246. PubMed ID: 27460780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
